The Association of Cytomegalovirus IgM and Allostatic Load
Abstract
:1. Introduction
1.1. Epidemiology of Cytomegalovirus
Clinical/Laboratory Diagnosis
1.2. Allostatic Load and Health
1.3. Sociodemographic Factors and Allostatic Load
1.4. Sociodemographic Factors and CMV Exposure Risk
1.5. Study Objectives
2. Materials and Methods
2.1. Population in Study
2.2. Operationalizing Allostatic Load
2.3. Measurement of Study Variables
2.4. Description of Study Variables
2.5. Statistical Analysis
3. Results
3.1. Characteristics of Study Participants
3.2. Association of Allostatic Load and CMV
4. Discussion
Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Cannon, M.J.; Schmid, D.S.; Hyde, T.B. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev. Med. Virol. 2010, 20, 202–213. [Google Scholar] [CrossRef] [PubMed]
- Hummel, M.; Abecassis, M.M. A model for reactivation of CMV from latency. J. Clin. Virol. 2002, 25, 123–136. [Google Scholar] [CrossRef]
- Bulka, C.M.; Bommarito, P.A.; Aiello, A.E.; Fry, R.C. Cytomegalovirus seroprevalence, recurrence, and antibody levels: Associations with cadmium and lead exposures in the general United States population. Environ. Epidemiol. 2020, 4, e100. [Google Scholar] [CrossRef] [PubMed]
- Hamilton, S.T.; Scott, G.; Naing, Z.; Iwasenko, J.; Hall, B.; Graf, N.; Arbuckle, S.; Craig, M.E.; Rawlinson, W.D. Human cytomegalovirus-induces cytokine changes in the placenta with implications for adverse pregnancy outcomes. PLoS ONE 2012, 7, e52899. [Google Scholar] [CrossRef] [PubMed]
- Limaye, A.P.; Boeckh, M. CMV in critically ill patients: Pathogen or bystander? Rev. Med. Virol. 2010, 20, 372–379. [Google Scholar] [CrossRef] [PubMed]
- Jahan, M. Laboratory diagnosis of CMV infection: A review. Bangladesh J. Med. Microbiol. 2010, 4, 39–44. [Google Scholar] [CrossRef]
- Basson, J.; Tardy, J.; Aymard, M. Pattern of anti-cytomegalovirus IgM antibodies determined by immunoblotting. Arch. Virol. 1989, 108, 259–270. [Google Scholar] [CrossRef]
- Nielsen, S.L.; Sörensen, I.; Andersen, H.K. Kinetics of specific immunoglobulins M, E, A, and G in congenital, primary, and secondary cytomegalovirus infection studied by antibody-capture enzyme-linked immunosorbent assay. J. Clin. Microbiol. 1988, 26, 654–661. [Google Scholar] [CrossRef]
- Stagno, S.; Tinker, M.; Elrod, C.; Fuccillo, D.; Cloud, G.; O’beirne, A. Immunoglobulin M antibodies detected by enzyme-linked immunosorbent assay and radioimmunoassay in the diagnosis of cytomegalovirus infections in pregnant women and newborn infants. J. Clin. Microbiol. 1985, 21, 930–935. [Google Scholar] [CrossRef] [PubMed]
- Guidi, J.; Lucente, M.; Sonino, N.; Fava, G.A. Allostatic load and its impact on health: A systematic review. Psychother. Psychosom. 2021, 90, 11–27. [Google Scholar] [CrossRef]
- McEwen, B.S.; Stellar, E. Stress and the individual: Mechanisms leading to disease. Arch. Intern. Med. 1993, 153, 2093–2101. [Google Scholar] [CrossRef] [PubMed]
- Seeman, T.E.; Singer, B.H.; Rowe, J.W.; Horwitz, R.I.; McEwen, B.S. Price of adaptation—Allostatic load and its health consequences: MacArthur studies of successful aging. Arch. Intern. Med. 1997, 157, 2259–2268. [Google Scholar] [CrossRef]
- Sterling, P. Principles of allostasis: Optimal design, predictive regulation, pathophysiology, and rational therapeutics. Allostasis Homeost. Costs Physiol. Adapt. 2004, 17, 17–64. [Google Scholar]
- Theall, B.; Wang, H.; Kuremsky, C.A.; Cho, E.; Hardin, K.; Robelot, L.; Marucci, J.; Mullenix, S.; Lemoine Jr, N.; Johannsen, N.M. Allostatic stress load and CMV serostatus impact immune response to maximal exercise in collegiate swimmers. J. Appl. Physiol. 2020, 128, 178–188. [Google Scholar] [CrossRef] [PubMed]
- Petrovic, D.; Pivin, E.; Ponte, B.; Dhayat, N.; Pruijm, M.; Ehret, G.; Ackermann, D.; Guessous, I.; Younes, S.E.; Pechère-Bertschi, A.; et al. Sociodemographic, behavioral and genetic determinants of allostatic load in a Swiss population—Based study. Psychoneuroendocrinology 2016, 67, 76–85. [Google Scholar] [CrossRef]
- Rainisch, B.K.W.; Upchurch, D.M. Sociodemographic Correlates of Allostatic Load Among a National Sample of Adolescents: Findings From the National Health and Nutrition Examination Survey, 1999–2008. J. Adolesc. Health 2013, 53, 506–511. [Google Scholar] [CrossRef]
- Miller, H.N.; LaFave, S.; Marineau, L.; Stephens, J.; Thorpe Jr, R.J. The impact of discrimination on allostatic load in adults: An integrative review of literature. J. Psychosom. Res. 2021, 146, 110434. [Google Scholar] [CrossRef]
- Geronimus, A.T.; Hicken, M.; Keene, D.; Bound, J. “Weathering” and age patterns of allostatic load scores among blacks and whites in the United States. Am. J. Public Health 2006, 96, 826–833. [Google Scholar] [CrossRef]
- Hecker, M.; Qiu, D.; Marquardt, K.; Bein, G.; Hackstein, H. Continuous cytomegalovirus seroconversion in a large group of healthy blood donors. Vox Sang. 2004, 86, 41–44. [Google Scholar] [CrossRef] [PubMed]
- Colugnati, F.A.; Staras, S.A.; Dollard, S.C.; Cannon, M.J. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect. Dis. 2007, 7, 71. [Google Scholar] [CrossRef] [PubMed]
- Barnes, L.L.; Capuano, A.W.; Aiello, A.E.; Turner, A.D.; Yolken, R.H.; Torrey, E.F.; Bennett, D.A. Cytomegalovirus infection and risk of Alzheimer disease in older black and white individuals. J. Infect. Dis. 2015, 211, 230–237. [Google Scholar] [CrossRef] [Green Version]
- Dowd, J.B.; Aiello, A.E.; Alley, D.E. Socioeconomic disparities in the seroprevalence of cytomegalovirus infection in the US population: NHANES III. Epidemiol. Infect. 2009, 137, 58–65. [Google Scholar] [CrossRef]
- Antona, D.; Lepoutre, A.; Fonteneau, L.; Baudon, C.; Halftermeyer-Zhou, F.; Le Strat, Y.; LÉVy-Bruhl, D. Seroprevalence of cytomegalovirus infection in France in 2010. Epidemiol. Infect. 2017, 145, 1471–1478. [Google Scholar] [CrossRef] [PubMed]
- Lachmann, R.; Loenenbach, A.; Waterboer, T.; Brenner, N.; Pawlita, M.; Michel, A.; Thamm, M.; Poethko-Müller, C.; Wichmann, O.; Wiese-Posselt, M. Cytomegalovirus (CMV) seroprevalence in the adult population of Germany. PLoS ONE 2018, 13, e0200267. [Google Scholar] [CrossRef]
- Markides, K.S.; Rote, S. The healthy immigrant effect and aging in the United States and other western countries. Gerontologist 2019, 59, 205–214. [Google Scholar] [CrossRef]
- Zuhair, M.; Smit, G.S.A.; Wallis, G.; Jabbar, F.; Smith, C.; Devleesschauwer, B.; Griffiths, P. Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta—Analysis. Rev. Med. Virol. 2019, 29, e2034. [Google Scholar] [CrossRef] [PubMed]
- Obeng-Gyasi, E.; Obeng-Gyasi, B. Chronic stress and cardiovascular disease among individuals exposed to lead: A pilot study. Diseases 2020, 8, 7. [Google Scholar] [CrossRef] [PubMed]
- Bahreinian, S.; Ball, G.D.; Vander Leek, T.K.; Colman, I.; McNeil, B.J.; Becker, A.B.; Kozyrskyj, A.L. Allostatic load biomarkers and asthma in adolescents. Am. J. Respir. Crit. Care Med. 2013, 187, 144–152. [Google Scholar] [CrossRef] [PubMed]
- Bashir, T.; Asiseh, F.; Jefferson-Moore, K.; Obeng-Gyasi, E. The Association of Per-and Polyfluoroalkyl Substances Serum Levels and Allostatic Load by Country of Birth and the Length of Time in the United States. Int. J. Environ. Res. Public Health 2022, 19, 9438. [Google Scholar] [CrossRef] [PubMed]
- Meyer, J. Age: 2000: Census 2000 Brief; DIANE Publishing: Washington, DC, USA, 2008. [Google Scholar]
- Dollard, S.C.; Staras, S.A.; Amin, M.M.; Schmid, D.S.; Cannon, M.J. National prevalence estimates for cytomegalovirus IgM and IgG avidity and association between high IgM antibody titer and low IgG avidity. Clin. Vaccine Immunol. 2011, 18, 1895–1899. [Google Scholar] [CrossRef] [PubMed]
- Agarwal, A.; Kumari, N.; Trehan, A.; Khadwal, A.; Dogra, M.R.; Gupta, V.; Sharma, A.; Gupta, A.; Singh, R. Outcome of cytomegalovirus retinitis in immunocompromised patients without Human Immunodeficiency Virus treated with intravitreal ganciclovir injection. Graefe’s Arch. Clin. Exp. Ophthalmol. 2014, 252, 1393–1401. [Google Scholar] [CrossRef] [PubMed]
- Galiatsatos, P.; Shrier, I.; Lamoureux, E.; Szilagyi, A. Meta-analysis of outcome of cytomegalovirus colitis in immunocompetent hosts. Dig. Dis. Sci. 2005, 50, 609–616. [Google Scholar] [CrossRef] [PubMed]
- Seeman, T.E.; Singer, B.H.; Ryff, C.D.; Love, G.D.; Levy-Storms, L. Social relationships, gender, and allostatic load across two age cohorts. Psychosom. Med. 2002, 64, 395–406. [Google Scholar] [CrossRef] [PubMed]
- Crimmins, E.M.; Johnston, M.; Hayward, M.; Seeman, T. Age differences in allostatic load: An index of physiological dysregulation. Exp. Gerontol. 2003, 38, 731–734. [Google Scholar] [CrossRef]
- van Boven, M.; van de Kassteele, J.; Korndewal, M.J.; van Dorp, C.H.; Kretzschmar, M.; van der Klis, F.; de Melker, H.E.; Vossen, A.C.; van Baarle, D. Infectious reactivation of cytomegalovirus explaining age-and sex-specific patterns of seroprevalence. PLoS Comput. Biol. 2017, 13, e1005719. [Google Scholar] [CrossRef] [PubMed]
- Tampubolon, G.; Maharani, A. Trajectories of allostatic load among older Americans and Britons: Longitudinal cohort studies. BMC Geriatr. 2018, 18, 255. [Google Scholar] [CrossRef]
- Obeng-Gyasi, E. Cumulative effects of low-level lead exposure and chronic physiological stress on hepatic dysfunction—A preliminary study. Med. Sci. 2020, 8, 30. [Google Scholar] [CrossRef]
- Lübeck, P.R.; Doerr, H.W.; Rabenau, H.F. Epidemiology of human cytomegalovirus (HCMV) in an urban region of Germany: What has changed? Med. Microbiol. Immunol. 2010, 199, 53–60. [Google Scholar] [CrossRef]
- Bate, S.L.; Dollard, S.C.; Cannon, M.J. Cytomegalovirus seroprevalence in the United States: The national health and nutrition examination surveys, 1988–2004. Clin. Infect. Dis. 2010, 50, 1439–1447. [Google Scholar] [CrossRef]
- Dowd, J.B.; Haan, M.N.; Blythe, L.; Moore, K.; Aiello, A.E. Socioeconomic gradients in immune response to latent infection. Am. J. Epidemiol. 2008, 167, 112–120. [Google Scholar] [CrossRef]
- Hamdi, N.R.; South, S.C.; Krueger, R.F. Does education lower allostatic load? A co-twin control study. Brain Behav. Immun. 2016, 56, 221–229. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ding, X.; Barban, N.; Mills, M.C. Educational attainment and allostatic load in later life: Evidence using genetic markers. Prev. Med. 2019, 129, 105866. [Google Scholar] [CrossRef] [PubMed]
- Suvarna, B.; Suvarna, A.; Phillips, R.; Juster, R.-P.; McDermott, B.; Sarnyai, Z. Health risk behaviours and allostatic load: A systematic review. Neurosci. Biobehav. Rev. 2020, 108, 694–711. [Google Scholar] [CrossRef] [PubMed]
- Hawkley, L.C.; Lavelle, L.A.; Berntson, G.G.; Cacioppo, J.T. Mediators of the relationship between socioeconomic status and allostatic load in the Chicago Health, Aging, and Social Relations Study (CHASRS). Psychophysiology 2011, 48, 1134–1145. [Google Scholar] [CrossRef] [PubMed]
- Gustafsson, P.E.; Janlert, U.; Theorell, T.; Westerlund, H.; Hammarström, A. Socioeconomic status over the life course and allostatic load in adulthood: Results from the Northern Swedish Cohort. J. Epidemiol. Community Health 2011, 65, 986–992. [Google Scholar] [CrossRef]
- Burkes, R.; Osterburg, A.; Hwalek, T.; Lach, L.; Panos, R.J.; Borchers, M.T. Cytomegalovirus Seropositivity is Associated with Airflow Limitation in a Cohort of Veterans with a High Prevalence of Smoking. Chronic Obstr. Pulm. Dis. J. COPD Found. 2021, 8, 441. [Google Scholar] [CrossRef]
- Bashir, T.; Obeng-Gyasi, E. The Association between Multiple Per-and Polyfluoroalkyl Substances’ Serum Levels and Allostatic Load. Int. J. Environ. Res. Public Health 2022, 19, 5455. [Google Scholar] [CrossRef]
- Cawley, J.; Biener, A.; Meyerhoefer, C.; Ding, Y.; Zvenyach, T.; Smolarz, B.G.; Ramasamy, A. Direct medical costs of obesity in the United States and the most populous states. J. Manag. Care Spec. Pharm. 2021, 27, 354–366. [Google Scholar] [CrossRef]
- Lavretsky, H.; Newhouse, P.A. Stress, inflammation, and aging. Am. J. Geriatr. Psychiatry 2012, 20, 729–733. [Google Scholar] [CrossRef] [Green Version]
Characteristic | Overall | Low AL (N = 8,100,520) | High AL (N = 6,361,368) |
---|---|---|---|
Age | 35.10 (8.74) | 32.99 (8.33) | 37.77 (8.53) |
Sex | |||
Female | 7,562,431.22 (52.29%) | 4,424,015.71 (54.61%) | 3,138,415.51 (49.34%) |
Male | 6,899,456.71 (47.71%) | 3,676,503.88 (45.39%) | 3,222,952.82 (50.66%) |
Race/Ethnicity | |||
NH_White | 8,755,868.44 (60.54%) | 4,713,956.77 (58.19%) | 4,041,911.67 (63.54%) |
Mexican American | 2,433,690.81 (16.83%) | 1,508,167.40 (18.62%) | 925,523.41 (14.55%) |
NH_Black | 3,017,833.87 (20.87%) | 1,712,032.44 (21.13%) | 1,305,801.43 (20.53%) |
Other and/or Multiracial | 254,494.82 (1.76%) | 166,362.99 (2.05%) | 88,131.83 (1.39%) |
Other Hispanic | 0.00 (0.00%) | 0.00 (0.00%) | 0.00 (0.00%) |
Annual Family Income | |||
USD0–USD4999 | 798,096.32 (5.67%) | 487,910.01 (6.14%) | 310,186.31 (5.07%) |
USD10,000–USD14,999 | 1,100,662.64 (7.82%) | 728,671.23 (9.17%) | 371,991.41 (6.08%) |
USD15,000–USD19,999 | 963,166.68 (6.84%) | 579,145.22 (7.29%) | 384,021.46 (6.27%) |
USD20,000–USD24,999 | 1,387,409.11 (9.86%) | 776,977.53 (9.78%) | 610,431.58 (9.97%) |
USD25,000–USD34,999 | 1,442,052.01 (10.25%) | 850,959.31 (10.71%) | 591,092.70 (9.65%) |
USD35,000–USD44,999 | 1,186,327.32 (8.43%) | 646,896.07 (8.14%) | 539,431.25 (8.81%) |
USD45,000–USD54,999 | 1,194,416.14 (8.49%) | 703,122.98 (8.85%) | 491,293.16 (8.02%) |
USD5000–USD9999 | 646,050.03 (4.59%) | 323,317.27 (4.07%) | 322,732.77 (5.27%) |
USD55,000–USD64,999 | 1,065,592.88 (7.57%) | 458,237.05 (5.77%) | 607,355.83 (9.92%) |
USD65,000–USD74,999 | 1,033,293.71 (7.34%) | 522,564.04 (6.57%) | 510,729.67 (8.34%) |
USD75,000 and over | 3,029,142.64 (21.53%) | 1,720,581.87 (21.65%) | 1,308,560.77 (21.37%) |
Over USD20,000 | 103,235.58 (0.73%) | 59,917.36 (0.75%) | 43,318.22 (0.71%) |
Under USD20,000 | 122,412.88 (0.87%) | 90,252.31 (1.14%) | 32,160.57 (0.53%) |
Education Level | |||
9–11th grade (Includes 12th grade with no diploma) | 2,220,959.16 (15.41%) | 950,641.84 (11.80%) | 1,270,317.32 (19.97%) |
College graduate or above | 1,934,563.35 (13.42%) | 896,940.76 (11.14%) | 1,037,622.60 (16.31%) |
High school graduate/GED or equivalent | 4,695,534.31 (32.57%) | 2,835,243.24 (35.20%) | 1,860,291.07 (29.24%) |
Less than 9th grade | 1,122,346.49 (7.79%) | 577,767.99 (7.17%) | 544,578.50 (8.56%) |
Some college or AA degree | 4,442,683.58 (30.82%) | 2,794,124.73 (34.69%) | 1,648,558.85 (25.92%) |
Alcohol Consumption | |||
Yes | 10,073,294.98 (73.00%) | 5,837,655.26 (75.90%) | 4,235,639.72 (69.35%) |
No | 3,725,709.73 (27.00%) | 1,853,574.58 (24.10%) | 1,872,135.14 (30.65%) |
Currently Smoking | |||
Yes | 4,451,670.38 (66.48%) | 2,430,938.28 (68.23%) | 2,020,732.10 (64.49%) |
No | 2,244,241.49 (33.52%) | 1,131,684.89 (31.77%) | 1,112,556.60 (35.51%) |
Cigarette Smoker | |||
Yes | 6,695,911.87 (46.30%) | 3,562,623.17 (43.98%) | 3,133,288.70 (49.25%) |
No | 7,765,976.06 (53.70%) | 4,537,896.43 (56.02%) | 3,228,079.63 (50.75%) |
Physical Activity | |||
No | 10,042,801.29 (69.44%) | 5,204,263.64 (64.25%) | 4,838,537.65 (76.06%) |
Unable to Do | 153,778.94 (1.06%) | 58,332.04 (0.72%) | 95,446.90 (1.50%) |
Yes | 4,265,307.71 (29.49%) | 2,837,923.92 (35.03%) | 1,427,383.79 (22.44%) |
Number of muscle-strengthening activities in the last 30 days | 15.45 (18.36) | 15.53 (12.10) | 15.27 (26.79) |
Unknown | 10,196,580 | 5,262,596 | 4,933,985 |
CMV IGM | |||
Negative | 14,258,317.17 (98.59%) | 7,987,151.56 (98.60%) | 6,271,165.61 (98.58%) |
Positive | 203,570.77 (1.41%) | 113,368.04 (1.40%) | 90,202.72 (1.42%) |
Avg Systolic BP | 115.93 (14.14) | 111.20 (10.89) | 121.96 (15.46) |
Avg Diastolic BP | 72.03 (11.23) | 68.85 (10.15) | 76.08 (11.25) |
HDL | 49.63 (14.44) | 53.08 (12.98) | 45.23 (15.03) |
Total Cholesterol | 193.61 (40.78) | 181.01 (31.40) | 209.66 (45.50) |
Triglyceride | 132.81 (105.18) | 96.51 (48.18) | 179.04 (135.68) |
HbA1C | 5.32 (0.63) | 5.17 (0.33) | 5.51 (0.83) |
Albumin, Urine | 34.81 (7.72) | 29.06 (10.81) | 42.12 (10.32) |
BMI | 27.84 (6.12) | 25.39 (4.49) | 30.96 (6.49) |
Creatinine, Urine | 154.38 (86.36) | 168.63 (85.53) | 136.25 (84.12) |
C-Reactive Protein | 0.38 (0.78) | 0.26 (0.88) | 0.53 (0.60) |
Characteristic | Overall (N = 58,254,118) | CMV IgM Negative, N = 57,352,826 | CMV IgM Positive, N = 901,292 |
---|---|---|---|
Age | 35.29 (8.59) | 35.36 (8.57) | 30.40 (8.57) |
Sex | |||
Female | 32,640,056.76 (56.03%) | 31,954,897.51 (55.72%) | 685,159.24 (76.02%) |
Male | 25,614,061.41 (43.97%) | 25,397,928.36 (44.28%) | 216,133.05 (23.98%) |
Race/Ethnicity | |||
NH_White | 35,119,201.45 (60.29%) | 34,460,451.74 (60.09%) | 658,749.71 (73.09%) |
Mexican American | 10,285,217.38 (17.66%) | 10,188,226.98 (17.76%) | 96,990.40 (10.76%) |
NH_Black | 12,077,990.97 (20.73%) | 11,932,438.79 (20.81%) | 145,552.18 (16.15%) |
Other and/or Multiracial | 771,708.36 (1.32%) | 771,708.36 (1.35%) | 0.00 (0.00%) |
Other Hispanic | 0.00 (0.00%) | 0.00 (0.00%) | 0.00 (0.00%) |
Annual Family Income | |||
USD0–USD4999 | 2,996,142.19 (5.26%) | 2,944,929.53 (5.25%) | 51,212.66 (5.68%) |
USD5000–USD9999 | 3,367,630.93 (5.91%) | 3,271,869.09 (5.83%) | 95,761.83 (10.62%) |
USD10,000–USD14,999 | 5,224,259.19 (9.17%) | 5,192,909.53 (9.26%) | 31,349.65 (3.48%) |
USD15,000–USD19,999 | 4,190,027.73 (7.35%) | 4,155,385.69 (7.41%) | 34,642.04 (3.84%) |
USD20,000–USD24,999 | 5,183,282.06 (9.09%) | 5,098,891.05 (9.09%) | 84,391.01 (9.36%) |
USD25,000–USD34,999 | 6,605,132.96 (11.59%) | 6,489,300.22 (11.57%) | 115,832.73 (12.85%) |
USD35,000–USD44,999 | 5,146,442.16 (9.03%) | 5,012,278.56 (8.94%) | 134,163.60 (14.89%) |
USD45,000–USD54,999 | 5,390,253.42 (9.46%) | 5,332,968.88 (9.51%) | 57,284.54 (6.36%) |
USD55,000–USD64,999 | 3,726,513.41 (6.54%) | 3,726,513.41 (6.64%) | 0.00 (0.00%) |
USD65,000–USD74,999 | 3,395,690.40 (5.96%) | 3,351,282.11 (5.97%) | 44,408.28 (4.93%) |
USD75,000 and over | 10,440,089.54 (18.32%) | 10,187,843.59 (18.16%) | 252,245.94 (27.99%) |
Over USD20,000 | 659,204.30 (1.16%) | 659,204.30 (1.18%) | 0.00 (0.00%) |
Under USD20,000 | 667,756.64 (1.17%) | 667,756.64 (1.19%) | 0.00 (0.00%) |
Education Level | |||
9–11th grade (Includes 12th grade with no diploma) | 9,471,651.40 (16.27%) | 9,421,651.27 (16.44%) | 50,000.13 (5.55%) |
College graduate or above | 9,508,020.97 (16.33%) | 9,342,110.06 (16.30%) | 165,910.91 (18.41%) |
High school graduate/GED or equivalent | 16,888,929.50 (29.01%) | 16,625,057.36 (29.01%) | 263,872.15 (29.28%) |
Less than 9th grade | 4,082,106.67 (7.01%) | 4,068,153.41 (7.10%) | 13,953.27 (1.55%) |
Some college or AA degree | 18,257,608.58 (31.37%) | 17,850,052.74 (31.15%) | 407,555.84 (45.22%) |
Alcohol Consumption | |||
Yes | 20,322,664.55 (73.52%) | 19,983,797.49 (73.37%) | 338,867.06 (83.29%) |
No | 7,320,995.64 (26.48%) | 7,253,009.44 (26.63%) | 67,986.20 (16.71%) |
Currently Smoking | |||
Yes | 19,040,473.81 (67.43%) | 18,704,233.91 (67.38%) | 336,239.90 (70.49%) |
No | 9,195,523.88 (32.57%) | 9,054,753.15 (32.62%) | 140,770.73 (29.51%) |
Cigarette Smoker | |||
Yes | 28,235,997.68 (48.48%) | 27,758,987.05 (48.41%) | 477,010.63 (52.93%) |
No | 29,995,710.66 (51.51%) | 29,571,429.00 (51.58%) | 424,281.66 (47.07%) |
Physical Activity | |||
No | 40,948,234.07 (70.29%) | 40,395,511.41 (70.43%) | 552,722.66 (61.33%) |
Unable to Do | 713,335.11 (1.22%) | 693,718.06 (1.21%) | 19,617.05 (2.18%) |
Yes | 16,592,548.98 (28.48%) | 16,263,596.40 (28.36%) | 328,952.58 (36.50%) |
Number of times spent muscle strengthening in the last 30 days | 14.58 (17.41) | 14.45 (17.22) | 20.62 (24.71) |
Unknown | 41,661,569 | 41,089,229 | 572,340 |
Avg Systolic BP | 116.52 (14.32) | 116.63 (14.36) | 109.55 (8.34) |
Avg Diastolic BP | 71.55 (11.86) | 71.59 (11.92) | 69.11 (6.34) |
HDL | 50.21 (14.49) | 50.15 (14.49) | 54.63 (14.40) |
Total Cholesterol | 197.03 (41.43) | 197.12 (41.43) | 191.20 (41.79) |
Triglyceride | 135.15 (136.51) | 135.32 (137.39) | 124.23 (58.04) |
HbA1C | 5.35 (0.75) | 5.35 (0.75) | 5.37 (1.07) |
Albumin, Urine | 24.68 (3.10) | 24.96 (3.13) | 6.54 (0.82) |
BMI | 28.25 (6.50) | 28.28 (6.51) | 26.42 (5.86) |
Creatinine, Urine | 145.30 (86.51) | 145.79 (86.73) | 113.60 (64.53) |
C-Reactive Protein | 0.43 (0.85) | 0.43 (0.86) | 0.40 (0.51) |
AL | |||
Low | 8,100,519.60 (56.01%) | 7,987,151.56 (56.02%) | 113,368.04 (55.69%) |
High | 6,361,368.33 (43.99%) | 6,271,165.61 (43.98%) | 90,202.72 (44.31%) |
Model Variables | * Adjusted OR (95% CI) | p-Value |
---|---|---|
* CMV IgM | ||
Positive | 0.4241 (0.0445, 4.0445) | 0.39834 |
Negative | Reference | |
Age | 1.0592 (1.0215 1.0983) | 0.00715 |
Sex | ||
Male | 1.5026 (0.6962, 3.2432) | 0.25092 |
Female | Reference | |
Race | ||
NH White | Reference | |
NH Black | 0.5427 (0.2532, 1.1631) | 0.0998 |
Mexican American | 1.0778 (0.4936, 2.3535) | 0.82695 |
Other/Multiracial | 1.9799 (0.0786 49.8863) | 0.63203 |
Alcohol | ||
Yes | 0.7796 (0.2495, 2.4363) | 0.62134 |
No | Reference | |
Smoking Now | ||
Yes | 0.9742 (0.3986, 2.3809) | 0.94679 |
No | Reference |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hill, M.; Obeng-Gyasi, E. The Association of Cytomegalovirus IgM and Allostatic Load. Diseases 2022, 10, 70. https://doi.org/10.3390/diseases10040070
Hill M, Obeng-Gyasi E. The Association of Cytomegalovirus IgM and Allostatic Load. Diseases. 2022; 10(4):70. https://doi.org/10.3390/diseases10040070
Chicago/Turabian StyleHill, Matthew, and Emmanuel Obeng-Gyasi. 2022. "The Association of Cytomegalovirus IgM and Allostatic Load" Diseases 10, no. 4: 70. https://doi.org/10.3390/diseases10040070